Apatinib Mesylate Clinical Trials
8 recruitingDrug
Phase 23Phase 33Not Applicable2Phase 11
Showing 1–8 of 8 trials
Recruiting
Phase 3
Study to Evaluate the Efficacy and Safety of Camrelizumab and Apatinib in Patients With GC/GEJC
Gastric Cancer
Jiangsu HengRui Medicine Co., Ltd.550 enrolled1 locationNCT04342910
Recruiting
Phase 3
Randomized, Open, Controlled, Multicenter Phase III Clinical Study of Fluzoparib in Combination With Apatinib Versus Investigator-Selected Chemotherapy for HRD-Positive/HER2-negative Advanced Breast Cancer
Fludzoparib" and Anti-angiogenicHRD-positive/HER2-negative Advanced Breast Cancer
Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University200 enrolled1 locationNCT06255392
Recruiting
Phase 2
A Study of Adebrelimab Combined With Apatinib Mesylate and Chemotherapy for Neoadjuvant Therapy and Biomarker Analysis in Limited-stage Small Cell Lung Cancer
Small Cell Lung Cancer Limited Stage
Jin Ying38 enrolled1 locationNCT06483282
Recruiting
Phase 2
Albumin-Bound Paclitaxel Combined With Antiangiogenic Agents in First-line Treatment of Relapsed or Metastatic TNBC
The First Affiliated Hospital of Bengbu Medical University128 enrolled1 locationNCT05192798
Recruiting
Phase 3
Camrelizumab Combined With Apatinib Mesylate and TACE in the Perioperative Treatment of Hepatocellular Carcinoma
Hepatocellular CarcinomaImmunotherapyPreoperative
The First Affiliated Hospital with Nanjing Medical University130 enrolled1 locationNCT05613478
Recruiting
Not Applicable
Apatinib in the Treatment of Recurrent Atypical/malignant Meningioma in Adults
Recurrent Atypical/malignant Meningioma
Beijing Sanbo Brain Hospital29 enrolled1 locationNCT04501705
Recruiting
Phase 1Phase 2
Apatinib Combined with Albumin-Bound Paclitaxel for Treatment of Advanced Triple Negative Breast Cancer
Fujian Cancer Hospital29 enrolled1 locationNCT05019690
Recruiting
Not Applicable
Apatinib Mesylate Versus Standard Second-line TKI in the Treatment of Advanced GIST
Gastrointestinal Stromal Tumors
Xiangya Hospital of Central South University258 enrolled1 locationNCT05751733